Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus fluoxetine for major depressive disorder in Asian outpatients
ChiCTR-TRC-11001668Phase 3Completed
- Sponsor
- Servier
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine and fluoxetine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Change from baseline to week 8 in Hamilton Depression Rating Scale, 17-item total score. Started Aug 2006; status: completed.
02
Drugs
agomelatinefluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR-TRC-11001668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001668.